CD8A and lung cancer: For example, in anti-PD-1 resistant 344SQ metastatic lung cancer cells, the addition of intratumoral α-OX40 following SBRT (36 Gy in three fractions) improves local control, abscopal effects, and survival by augmenting CD8+ T cell expansion and infiltration in the TME [27].